---
layout: default
title: Remdesivir
parent: Model Prediction Only (L5)
nav_order: 726
evidence_level: L5
indication_count: 10
---

# Remdesivir
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Remdesivir: From COVID-19 to Multiple Endocrine Neoplasia

## One-Sentence Summary

Remdesivir is an RNA-dependent RNA polymerase (RdRp) inhibitor internationally known for treating COVID-19 (SARS-CoV-2 infection), though it is not currently marketed in India and formal original-indication text is unavailable in the local regulatory record. The TxGNN model predicts potential efficacy for **Multiple Endocrine Neoplasia (MEN)**, but this direction is currently supported by **0 clinical trials** and **0 publications**, and the underlying rationale itself flags the prediction as a likely spurious model artifact.

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available from India regulatory licenses (drug not marketed); internationally used for COVID-19 (SARS-CoV-2) treatment |
| Predicted New Indication | Multiple Endocrine Neoplasia |
| TxGNN Prediction Score | 99.50% |
| Evidence Level | L5 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed formal mechanism-of-action data for Remdesivir is currently a data gap in this evidence pack. Based on the evidence pack's own repurposing rationale, Remdesivir acts as an RNA-dependent RNA polymerase (RdRp) inhibitor, targeting viral replication in RNA viruses such as SARS-CoV-2 and Ebola virus — consistent with its well-documented use across the large body of COVID-19 clinical trials contained in this pack (e.g., NCT04292730, NCT04292899, ACTT-3).

Multiple Endocrine Neoplasia (MEN), by contrast, is a hereditary tumor syndrome driven by germline mutations in RET or MEN1 genes, with no known relationship to viral RNA replication or antiviral pharmacology. There is no plausible biological pathway connecting an RdRp inhibitor to endocrine tumorigenesis.

**This prediction should not be treated as biologically reasonable.** The evidence pack's own rationale explicitly assesses this as a likely **spurious association (embedding-space artifact)** — the high TxGNN score is not accompanied by any mechanistic hypothesis, clinical trial, or literature signal, which is the defining pattern of an unsupported model output rather than a genuine repurposing candidate.

## Clinical Trial Evidence

Currently no related clinical trials registered

## Literature Evidence

Currently no related literature available

## India Market Information

Remdesivir currently has no registration records in the India regulatory dataset (market status: Not Marketed, 0 licenses on file).

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Despite a high TxGNN prediction score, there is zero clinical trial or literature evidence for Remdesivir in Multiple Endocrine Neoplasia, and no plausible mechanistic link exists between an RdRp inhibitor and a RET/MEN1-driven tumor syndrome. The evidence pack's own analysis characterizes this as a likely spurious model association rather than a genuine repurposing signal — this does not meet the bar to advance past S0.

**To proceed, the following is needed:**
- A genuine mechanistic hypothesis or preclinical rationale linking Remdesivir to MEN pathophysiology before any further evaluation
- Resolution of blocking data gap DG001 (TFDA/India label warnings and contraindications) via official label PDF retrieval, required before any S1 safety screening
- Resolution of high-severity data gap DG002 (confirmed MOA) via DrugBank API query, to support or refute mechanistic plausibility for this and other candidates
- Note: other ranked candidates in this pack (HIV, SIV, leprosy, CMV) were also reviewed and found to rely on label-mismatched COVID-19 evidence rather than genuine indication-specific data — none currently support progression beyond Hold
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

